¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"protein/creatinine ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high-protein diet
    °í´Ü¹éÁú½Ä»ç
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • iron binding protein
    ö°áÇմܹéÁú
  • major basic protein
    ÁÖ¿ä±âÃʴܹéÁú, ÁÖ±âÀú´Ü¹éÁú
  • mitogen-activated protein kinase
    ¹ÌÅä°ÕȰ¼ºÈ­´Ü¹éÁúŰ³ª¾ÆÁ¦
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹éÁú, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • matrix protein
    ¹ÙÅÁÁú´Ü¹éÁú
  • membrane control protein
    ¸·Á¶Àý´Ü¹éÁú
  • olfactory binding protein
    Èİ¢°áÇմܹéÁú
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • principal outer membrane protein
    ÁÖ¹Ù±ù¸·´Ü¹éÁú, Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹéÁú
  • protein
    ´Ü¹éÁú
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
  • mitogen-activated protein kinase
    ºÐ¿­Á¦È°¼º´Ü¹éŰ³ª¾ÆÁ¦
  • protein kinase
    ´Ü¹éÁúŰ³ª¾ÆÁ¦
  • protein layer
    ´Ü¹éÁúÃþ
  • major basic protein
    ÁÖ±âÀú´Ü¹é, ÁÖ¿ä±âÃʴܹé
  • matrix protein
    ¹ÙÅÁÁú´Ü¹é
  • membrane control protein
    ¸·Á¶Àý´Ü¹é
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹é, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • olfactory binding protein
    Èİ¢°áÇմܹé
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • principal outer membrane protein
    Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹé
  • protein quotient
    ´Ü¹éÁö¼ö
  • protein score
    ´Ü¹é°¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inspiratory expiratory ratio
    ÈíÈ£±â´ëºñ.
  • phase ratio
    »óºñ(ßÓÝï).
  • primary sex ratio
    ÀÏÂ÷¼º ºñ(ÊÙËÛËÓ).
  • ratio
    ºñ(ËÓ).
  • ratio
    ºñ(Ýï)
  • ratio estimate
    ºñÃßÁ¤·®(ËÓÌ§ËøËâ).
  • ratio intelligence qoutient
    Áö´ÉºñÀ²Áö¼ö
  • ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • ratio of dependants
    ºÎ¾çºñ(ËÓËâËÓ).
  • AA protein
    ¾Æ¹Ð·ÎÀ̵åA´Ü¹é(¡­Ó±ÛÜ)
  • ABP=> androgen-binding protein
    ¾Èµå·ÎÁ¨°áÇմܹé
  • Bence Jones protein
    º¥½º-Á¸½º´Ü¹é.
  • Bence-Jones protein
    º¥½º-Á¸½º ´Ü¹éÁú
  • C protein
    C´Ü¹éÁú
  • C-Fos protein
    ¾¾-Æ÷½º´Ü¹é(Ó±ÛÜ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common ratio
    °øºñ(ÍëÝï)
  • common ratio
    °øºñ(Ë­ËÓ).
  • contrast enhancement ratio
    Á¶¿µ Áõ°­ºñ
  • contrast to noise ratio
    ´ëÁ¶ ÀâÀ½ºñ
  • correlation ratio
    »ó°üºñ(Ë×Ë´ËÓ).
  • cup-disc ratio
    À¯µÎÇÔ¸ôºñ
  • curative ratio
    Ä¡À¯À²(̬Ëô ).
  • depth to width ratio
    ±íÀÌ Æø ºñÀ²
  • dilution ratio
    ¹±Èûºñ(¡­Ýï), Èñ¼®ºñ.
  • distribution ratio
    ºÐÆ÷ºñÀ²
  • extraction ratio
    ÃßÃâ·ü(õÎõóëÒ).
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²(ÎßüµÝï×Ë).
  • gyromagnetic ratio
    ȸÀü Àڱ⠺ñÀ²
  • heart lung ratio =HLR
    ½ÉÆó°è¼ö(ãýøËÌõâ¦), ½ÉÈä(°û)ºñ(ãýýØÎ¬Ýï).
  • hydrodynamic ratio
    ¼ö·ÂÇÐ(Àû) ºñÀ²
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nucleo-cytoplasmic ratio
    ÇÙ(ú·).¼¼Æ÷Áú(á¬øàòõ) ºñ(Ýï)
  • packing ratio
    ÆäÅ·À²(ëÒ)
  • polarity ratio
    ±Ø¼º ºñÀ²(пàõÝï×Ë)
  • P:O ratio
    P/O ºñ
  • signal-to-noise ratio
    ½ÅÈ£/ÀâÀ½ºñ(ãáûÜ/íÚëåÝï)
  • viscosity ratio
    Á¡µµÀ²(ïÄÓøëÒ)
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ada protein
    ada ´Ü¹éÁú
  • adhesion protein
    ºÎÂø´Ü¹éÁú(ݾó·Ó±ÛÜòõ)
  • aldosterone-induced protein
    ¾Ëµµ½ºÅ×·ÐÀ¯µµ ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • A myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ) A
  • androgen-binding protein
    ¾Èµå·ÎÀü°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anion-transport protein
    À½À̿¿î¹Ý(ê¡Úõ) ´Ü¹éÁú(Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
Ccr Creatinine Clearance; 80 - 90 ml/min
CK   1) Creatine Kinase
  2) Creatinine Phosphokinase
CPK Creatinine Phospho-Kinase
  < 25(60)(200)(240) Unit
  Áõ°¡ÇÏ´Â °æ¿ì
 &n...
Cr, cr creatinine
Pcr Plasma Creatinine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CL(CR) Creatinine clearance
CRCL Creatinine clearance
CK Creatinine kinase
CPK Creatinine phosphokinase
Pcr Plasma creatinine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • bacterio protein
    ¼¼±Õ ´Ü¹éÁú
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • eosinophil protein X
    È£»ê±¸ ´Ü¹é X
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • hapten-protein conjugate
    ÇÕÅÙ ´Ü¹é °áÇÕ¹°
  • heat-aggregated protein
    ¿­ ÀÀÁý ´Ü¹é
  • hepatic protein
    °£ ´Ü¹é, °£ ´Ü¹éÁú
    °£ÀÇ ´Ü¹éÁú.
  • high protein diet
    °í´Ü¹é ½ÄÀÌ
  • membrane protein
    ¸· ´Ü¹éÁú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
case fatality ratio The mortality rate of a disease, usually expressed per 100 cases.
(05 Mar 2000)
CD4:CD8 ratio The ratio of CD4 to CD8 cells. A common measure of immune system status that is around two in healthy individuals. The ratio of T-lymphocytes that express the CD4 antigen to those that express the CD8 antigen. This value is commonly assessed in the diagnosis and staging of diseases affecting the immune system including HIV infection.
(12 Dec 1998)
reproductive ratio <epidemiology> 1. Basic reproductive ratio , Ro , a dimensionless parameter which encapsulates the biological details of different transmission mechanisms. For microparasites, Ro , is defined as the average number of secondary cases of infection to which one primary case gives rise throughout its infectious period if introduced into a defined population consisting solely of susceptible individuals. For macroparasites, Ro , is the average number of female offspring (or just offspring in the case of hermaphroditic species) produced throughout the lifetime of a mature female parasite, which themselves achieve reproductive maturity in the absence of density-dependent constraints on the parasite establishment, survival or reproduction.
Also known as the basic reproduction rate, number.
2. Effective reproductive ratio , R , The number of secondary cases (microparasites) or female offspring (macroparasites) produced in a host population not consisting entirely of susceptible individuals (microparasites) or within which density dependent constraints limit parasite population growth (macroparasites). Under conditions of stable endemic infection, R=1.
(05 Dec 1998)
respiratory exchange ratio The ratio of the net output of carbon dioxide to the simultaneous net uptake of oxygen at a given site, both expressed as moles or STPD volumes per unit time; in the steady state, respiratory exchange ratio is equal to the respiratory quotient of metabolic processes.
(05 Mar 2000)
mendelian ratio The ratio of progeny with a particular phenotypes or genotypes expected in accordance with Mendel's law among the offspring of matings specified as to genotype or phenotype.
(05 Mar 2000)
M:E ratio The ratio of myeloid to erythroid precursors in bone marrow; normally it varies from 2:1 to 4:1; an increased ratio is found in infections, chronic myelogenous leukaemia, or erythroid hypoplasia; a decreased ratio may mean a depression of leukopoiesis or normoblastic hyperplasia depending on the overall cellularity of the bone marrow.
(05 Mar 2000)
grid ratio In a radiographic scatter-absorbing grid, the ratio of the height to the width of the gaps between lead strips; a higher grid ratio removes more scattered radiation but requires more careful X-ray tube positioning to avoid grid cutoff of the primary radiation beam.
(05 Mar 2000)
gyromagnetic ratio In nuclear magnetic resonance, the ratio of the magnetic dipole moment of the nucleus to the nuclear spin angular momentum; the gyromagnetic ratio is a unique value for each type of nucleus.
Synonym: magnetogyric ratio.
(05 Mar 2000)
molecular weight ratio The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units.
See: atomic weight.
Synonym: molecular mass, molecular weight ratio, relative molecular mass.
(05 Mar 2000)
P/O ratio A measure of oxidative phosphorylation; the ratio of phosphate radicals esterified (forming adenosine 5'-triphosphate from adenosine 5'-diphosphate) to atoms of oxygen consumed by mitochondria; normally, the ratio is 3 (starting from NADH).
Synonym: P/O quotient.
(05 Mar 2000)
hand ratio The ratio of the length of the hand (measured on the dorsum from the styloid process of the ulna to the tip of the third finger) to the width across the knuckles.
(05 Mar 2000)
segregation ratio In genetics, the proportion of progeny of a particular genotype or phenotype from actual matings of specified genotypes. The test of a Mendelian hypothesis is the comparison of the segregation rate with the Mendelian rate.
(05 Mar 2000)
sex ratio The number of males per 100 females.
(12 Dec 1998)
signal-to-noise ratio <microscopy> Also sometimes used as an abbreviation for serial number, can be somewhat confusing in the case of electronic equipment.
(05 Aug 1998)
split ratio The fraction of the cells in a fully grown culture of animal cells that should be used to start a subsequent culture. Minimum may be dictated by medium inadequacies that result in poor growth of some cells at high dilution.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á